Q-omics provides the consensus-scored BCKDK profile across patient tissues and cancer cell-line models. BCKDK expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, BCKDK is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, BCKDK RNA expression shows 16,893 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, KIRC, and ACC as cancer lineages where BCKDK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCKDK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCKDK survival associations across molecular data types. BCKDK RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCKDK RNA expression–survival associations across cancer types. High BCKDK expression shows unfavorable associations in BLCA, LAML, LGG and SKCM, but favorable associations in UCEC and READ. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify BLCA as the clearest survival context for BCKDK RNA expression.
This table summarizes BCKDK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BCKDK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCKDK shows lower tumor expression in KICH and higher tumor expression in KIRC, KIRP, LUAD, HNSC and BRCA. The KIRC box plot shows higher BCKDK RNA expression in tumor versus normal tissue (log2 FC = +1.263, t-test p < 0.001).
This table shows molecular features associated with BCKDK in patient tissues and cancer cell lines. In patient samples, BCKDK shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BCKDK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
